Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 3, 2004 Charly Travers	Sex Patch Returns to Lab FDA panel's safety concerns have sidetracked Proctor & Gamble's Intrinsa.
The Motley Fool February 14, 2011 Brian Orelli	This Biotech Is Heating Up Biosante Pharmaceuticals was up more than 9% at one point today after the company said the independent Data Monitoring Committee believed Biosante's female sexual dysfunction drug, LibiGel, was safe enough to allow the trial to continue.
The Motley Fool December 15, 2011 Brian Orelli	BioSante Shares Crushed by Placebo Effect BioSante's LibiGel efficacy is not deemed statistically significant.
BusinessWeek January 8, 2007 John Carey	A Little Blue Pill For Women? A German drugmaker has stumbled upon a substance that increases female arousal.
The Motley Fool November 9, 2007 Brian Orelli	P&G Gives Nastech a Bloody Nose Proctor & Gamble ends its partnership with Nastech Pharmaceutical to develop a nasal spray to treat osteoporosis.
Chemistry World November 18, 2009 Sarah Houlton	A pharmaceutical named desire A new drug being developed by Boehringer Ingelheim could give a boost to the sex drive of women with low libido.
The Motley Fool January 29, 2004 Alyce Lomax	All's Wella at P&G Wella's working, but will Procter & Gamble's stake in the German company help P&G take over the world?
The Motley Fool November 1, 2005 Nathan Parmelee	A Small Surprise From P&G Proctor & Gamble delivers, just like it promised, releasing first-quarter earnings that were actually a penny ahead of expectations.
American Family Physician May 15, 2004 Smucny & Park	Clinical Inquiries From the Family Practice Inquiries Network: Which antidepressant is best to avoid sexual dysfunction?
The Motley Fool December 14, 2011 David Williamson	BioSante Investors: It Was Nice While It Lasted Libigel loses to placebo in two studies, shares down 75% after hours.
The Motley Fool April 1, 2004 Bill Mann	P&G Unloads Sunny D Procter & Gamble sells its juice-based drink brand to J.W. Childs.
The Motley Fool December 28, 2006 Michael Leibert	Fool on the Street: P&G Still Going Strong Investors who believe that the consumer goods giant can achieve organic sales growth of 4% to 7% over the next few years might consider the current share price to be an attractive entry point to own a stake in an industry leader.
The Motley Fool August 31, 2010 Matt Koppenheffer	How Much Is Procter & Gamble Worth? Is Procter & Gamble's stock on sale?
The Motley Fool August 24, 2004 Steven Mallas	Procter & Gamble's Rising Tide The company tries putting two brands together in an attempt to capture sales. Investors in businesses that are oriented in the consumer sector love it when their company throws a bit of brand alchemy into the product line.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool October 27, 2004 Alyce Lomax	P&G Plows Along Investors got the jitters today, but Procter & Gamble's still strong.
The Motley Fool August 25, 2009 Mike Pienciak	Will P&G Ever Turn Around? Will the recently announced sale of its pharmaceutical business to specialty-drugs developer Warner Chilcott mark a turning point for Proctor & Gamble, or just another misstep?
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool August 2, 2004 Phil Wohl	P&G Is No Gamble The consumer products icon produces solid growth for its fourth quarter. The shares, which carry a dividend yield of 1.92%, are a great purchase for income investors.
BusinessWeek October 4, 2004 Berner et al.	P&G Has Rivals In A Wringer Colgate and Unilever are hurting as Proctor & Gamble rolls out creative products and marketing.
The Motley Fool January 28, 2011 Matt Koppenheffer	Procter & Gamble Shareholders Need Some Cheer Shares of Procter & Gamble take a dip after it announced fourth-quarter results.
The Motley Fool April 13, 2006 John Reeves	A Foolish Baby Shower: Procter & Gamble Few stocks have performed as well over the long term as Procter & Gamble. Clearly, this company is built to last. Investors, take note.
The Motley Fool July 6, 2009 Mike Pienciak	Desperately Seeking Greater Growth Procter & Gamble has plenty of heft, but its growth initiatives aren't exactly inspiring.
BusinessWeek September 2, 2010 Coleman-Lochner & Clothier	P&G Looks to Franchise Tide Dry Cleaning The world's largest consumer products company attached its branding to car washes three years ago. Now it wants to open hundreds of franchised Tide Dry Cleaners.
The Motley Fool May 2, 2007 Timothy M. Otte	P&G Loses the Expectations Game Analysts aren't impressed with the conglomerate's third-quarter results. Investors, take note.
The Motley Fool January 27, 2011 Rich Smith	What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash.
Chemistry World June 27, 2013 Phillip Broadwith	Ups and downs for erectile dysfunction drugs Spedra (avanafil) aims to compete for a share of the lucrative ED market, trading on the fact that it is much faster-acting than other available drugs.
The Motley Fool October 12, 2005 Steven Mallas	P&G Gambles on Prosperity Shareholders will have a nice stock on their hands for a while. Procter & Gamble sees steady growth four years out.
The Motley Fool August 3, 2006 Steven Mallas	A Prosperous P&G Procter & Gamble had a great year that was aided by the Gillette acquisition. This equity is a great long-term core holding; if you see it at an even higher yield, do yourself a favor and take a hard look at this stalwart operation.
The Motley Fool August 6, 2009 Colleen Paulson	Procter & Gamble Fights the Tide Global currency fluctuations and declining volume hurt P&G's profits in the fourth quarter.
The Motley Fool August 4, 2010 Matt Koppenheffer	Have You Sold Your Procter & Gamble Shares Yet? Procter & Gamble reported earnings that disappointed the market.
The Motley Fool July 16, 2010 Sean Sun	Stock Cheat Sheet: Procter & Gamble If you're new to Procter & Gamble, consider this your cheat sheet to get introduced to the consumer products giant.
The Motley Fool July 19, 2010 Eric Bleeker	Procter & Gamble's Tricky Ambitions Can it maintain margins while moving further into value segments?
The Motley Fool January 11, 2010 Mike Pienciak	Is P&G Overextending Itself? Recession-smacked Procter & Gamble may not be making all the right moves these days, but it certainly isn't sitting still, either.
The Motley Fool January 31, 2011 Andrew Bond	A Consumer Giant That's on the Cutting Edge Procter & Gamble's innovation comes from many sources.
The Motley Fool June 10, 2005 Steven Mallas	P&G's Pen Mightier Than the Stain Shareholders can count on P&G's resume when it comes to brand management and innovation. The company is leveraging its Tide brand for a smart new product.
The Motley Fool September 11, 2009 Mike Pienciak	Procter & Gamble Caves In to the Recession The consumer products giant is cutting prices to lure back customers.
The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool August 6, 2008 Timothy M. Otte	A Triple-Play Stock Consumer products giant Proctor & Gamble posts impressive fourth-quarter results.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool January 8, 2004 Rex Moore	P&G Ups Guidance, Again A severe cold and flu season plays in the company's favor.
The Motley Fool May 12, 2004 Brian Gorman	Procter & Gamble Bets on China The consumer products powerhouse looks like it's making all the right moves.
The Motley Fool October 26, 2010 Matt Koppenheffer	Can Procter & Gamble Defeat the Private Labels? Can P&G's latest marketing push help it reinvigorate sales in its largest market?
The Motley Fool February 27, 2008 Colleen Paulson	Making the Tough Decisions Delivering double-digit toothpaste and soap growth means that Procter & Gamble must be meticulous about cost control, and P&G has signaled once again that it will proactively manage its business to success.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
The Motley Fool January 26, 2006 Rich Smith	Foolish Forecast: Procter & Gamble Lathers Up If P&G continues to highlight the Household Care and Beauty businesses from the home team, and the Blades & Razors and Duracell & Braun divisions from Gillette as its star players, wise investors should give this stock a glance.
The Motley Fool August 3, 2007 Ryan Fuhrmann	Procter & Gamble Leads the Way In its fourth-quarter and full-year earnings conference call, Proctor & Gamble shows why it continues to dominate the global market in consumer goods.
The Motley Fool April 6, 2011 Matt Koppenheffer	Who Won in the Pringles Deal? Procter & Gamble and Diamond Foods investors face some changes now that P&G has sold them Pringles.
American Family Physician July 1, 2000	Sex Isn't Working for Me. What Can I Do? When you have problems with sex, doctors call it "sexual dysfunction." Men and women can have it. There are four kinds of sexual problems in women.